Skip to main content
Top
Published in: Investigational New Drugs 5/2011

01-10-2011 | SHORT REPORT

Ultraviolet recall dermatitis reaction with sorafenib

Authors: Nicolas Magné, Cyrus Chargari, Pierre Auberdiac, Coralie Moncharmont, Yacine Merrouche, Jean-Philippe Spano

Published in: Investigational New Drugs | Issue 5/2011

Login to get access

Summary

Purpose Recall dermatitis is a rare and poorly understood drug-related event. Activated by exposure to sunlight or Ultraviolet (UV), drug-related phototoxic reactions have been reported with conventional chemotherapy agents or antibiotics. Methods Here, we report the first case of acute dermatologic photo-induced recall reaction secondary to sorafenib in a patient with renal cell carcinoma. Results Four weeks after stopping sorafenib, a patient with renal cell carcinoma developed an acute erythematous and papulomatous eruption restricted to the hands after prolonged solar exposure. The erythematous region was very well demarcated, mimicking the cutaneous syndrome that the patient had presented at time he was receiving sorafenib. Conclusions The suppression of the phototoxic reaction by corticosteroids strongly suggests that the immune system may have an important function in photo-recall reactions.
Literature
1.
go back to reference Azria D, Magné N, Zouhair A et al (2005) Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 31:555–570PubMedCrossRef Azria D, Magné N, Zouhair A et al (2005) Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 31:555–570PubMedCrossRef
2.
go back to reference Badger J, Kang S, Uzieblo A, Srinivas S (2005) Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 23:7224–7225PubMedCrossRef Badger J, Kang S, Uzieblo A, Srinivas S (2005) Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 23:7224–7225PubMedCrossRef
3.
go back to reference Borroni G, Vassallo C, Brazzelli V et al (2004) Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol 26:213–216PubMedCrossRef Borroni G, Vassallo C, Brazzelli V et al (2004) Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol 26:213–216PubMedCrossRef
4.
go back to reference Camidge DR, Kunkler IH (2000) Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. Clin Oncol 12:272–273 Camidge DR, Kunkler IH (2000) Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. Clin Oncol 12:272–273
5.
go back to reference Chung C, Dawson LA, Joshua AM, Brade AM (2010) Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 21:206–209PubMedCrossRef Chung C, Dawson LA, Joshua AM, Brade AM (2010) Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 21:206–209PubMedCrossRef
6.
go back to reference Cho S, Breedlove JJ, Gunning ST (2008) Radiation recall reaction induced by levofloxacin. J Drugs Dermatol 7:64–67PubMed Cho S, Breedlove JJ, Gunning ST (2008) Radiation recall reaction induced by levofloxacin. J Drugs Dermatol 7:64–67PubMed
7.
go back to reference Dawson GA, Brown SI, Tellefsen L (2009) A drug-related phototoxic réaction and its possible Relationship to a radiation-induced skin réaction. Oncologist 14:303–306PubMedCrossRef Dawson GA, Brown SI, Tellefsen L (2009) A drug-related phototoxic réaction and its possible Relationship to a radiation-induced skin réaction. Oncologist 14:303–306PubMedCrossRef
8.
go back to reference Ee HL, Yosipovitch G (2003) Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 207:196–198PubMedCrossRef Ee HL, Yosipovitch G (2003) Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 207:196–198PubMedCrossRef
9.
go back to reference Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD (2007) Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 56:494–499PubMedCrossRef Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD (2007) Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 56:494–499PubMedCrossRef
10.
go back to reference Kodym E, Kalinska R, Ehringfeld C, Sterbik-Lamina A, Kodym R, Hohenberg G (2005) Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 28:18–21PubMedCrossRef Kodym E, Kalinska R, Ehringfeld C, Sterbik-Lamina A, Kodym R, Hohenberg G (2005) Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 28:18–21PubMedCrossRef
11.
go back to reference Magné N, Benezery K, Otto J, Namer M, Lagrange JL (2002) Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature. Cancer Radiothér 6:281–284PubMed Magné N, Benezery K, Otto J, Namer M, Lagrange JL (2002) Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature. Cancer Radiothér 6:281–284PubMed
12.
go back to reference Pierfitte C, Royer RJ, Moore N et al (2000) The link between sunshine and phototoxicity of sparfloxacin. Br J Clin Pharmacol 49:609–612PubMedCrossRef Pierfitte C, Royer RJ, Moore N et al (2000) The link between sunshine and phototoxicity of sparfloxacin. Br J Clin Pharmacol 49:609–612PubMedCrossRef
Metadata
Title
Ultraviolet recall dermatitis reaction with sorafenib
Authors
Nicolas Magné
Cyrus Chargari
Pierre Auberdiac
Coralie Moncharmont
Yacine Merrouche
Jean-Philippe Spano
Publication date
01-10-2011
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9476-5

Other articles of this Issue 5/2011

Investigational New Drugs 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine